Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 20, 2008, Pages 5684-5688

  Ghosh, Arun K ^a   Gong, Gangli ^a   Grum Tokars, Valerie ^b   Mulhearn, Debbie C ^b   Baker, Susan C ^c   Coughlin, Melissa ^b   Prabhakar, Bellur S ^b   Sleeman, Katrina ^c   Johnson, Michael E ^b   Mesecar, Andrew D ^b  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Antiviral; Ester; Inhibitor; SARS 3CLpro; Synthesis

Indexed keywords

5 CHLOROPYRIDYL ESTER DERIVATIVE; 5 CHLOROPYRIDYLINDOLE 4 CARBOXYLATE DERIVATIVE; ANTIVIRUS AGENT; CHYMOTRYPSIN LIKE PROTEINASE INHIBITOR; GRL 0496; PROTEINASE INHIBITOR; PYRIDINE DERIVATIVE; SARS CORONAVIRUS CHYMOTRYPSIN LIKE PROTEASE; SARS CORONAVIRUS PAPAIN LIKE PROTEASE; UNCLASSIFIED DRUG; VIRUS ENZYME;

ARTICLE; DRUG BINDING; DRUG DESIGN; DRUG SYNTHESIS; IC 50; MOLECULAR DOCKING; NONHUMAN; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS INHIBITION;

ANIMALS; ANTIVIRAL AGENTS; CATALYTIC DOMAIN; CHEMISTRY, PHARMACEUTICAL; CYSTEINE ENDOPEPTIDASES; DRUG DESIGN; ESTERS; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN BINDING; SARS VIRUS; VIRAL PROTEINS;

SARS CORONAVIRUS;

EID: 53349165585     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.08.082     Document Type: Article

References (28)

1. World Health Organization, Communicable Disease Surveillance & Response, website: http://www.who.int/csr/sars/archive/2003_05_07a/en and http://www.who.int/csr/sars/country/en/country2003_08_15.pdf.
2. He J.-F., Peng G.-W., Min J., Yu D.-W., Liang W.-L., Zhang S.-Y., Xu R.-H., Zheng H.-Y., Wu X.-W., Xu J., Wang Z.-H., Fang L., Zhang X., Li H., Yan X.-G., Lu J.-H., Hu Z.-H., Huang J.-C., Wan Z.-Y., Hou J.-L., Lin J.-Y., Song H.-D., Wang S.-Y., Zhou X.-J., Zhang G.-W., Gu B.-W., Zheng H.-J., Zhang X.-L., He M., Zheng K., Wang B.-F., Fu G., Wang X.-N., Chen S.-J., Chen Z., Hao P., Tang H., Ren S.-X., Zhong Y., Guo Z.-M., Liu Q., Miao Y.-G., Kong X.-Y., He W.-Z., Li Y.-X., Wu C.-I., Zhao G.-P., Chiu R.W.K., Chim S.S.C., Tong Y.-K., Chan P.K.S., Tam J.S., and Lo Y.M.D. Science 303 (2004) 1666
3. Drosten C., Gunther S., Preiser W., van der Werf S., Brodt H.R., Becker S., Rabanau H., Panning M., Kolesnikova L., Fouchier R.A., Berger A., Burguiere A.M., Cinatl J., Eickmann M., Escriou N., Grywna K., Kramme S., Manuguerra J.C., Muller S., Rickerts V., Sturmer M., Vieth S., Klenk H.D., Osterhaus A.D., Schmitz H., and Doerr H.W. N. Engl. J. Med. 348 (2003) 1967
4. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., Tong S., Urbani C., Comer J.A., Lim W., Rollin P.E., Dowell S.F., Ling A.E., Humphrey C.D., Shieh W.J., Guarner J., Paddock C.D., Rota P., Fields B., DeRisi J., Yang J.Y., Cox N., Hughes J.M., LeDuc J.W., Bellini W.J., and Anderson L.J. N. Engl. J. Med. 348 (2003) 1953
5. Bartlam M., Yang H., and Rao Z. Curr. Opin. Struct. Biol. 15 (2005) 664
6. Thiel V., Ivanov K.A., Putics A., Hertzig T., Schelle B., Bayer S., Weibrich B., Snijder E.J., Rabenau H., Doerr H.W., Gorbalenya A.E., and Ziebuhr J. J. Gen. Virol. 84 (2003) 2305
7. Ziebuhr J. Curr. Top. Microbiol. Immunol. 287 (2005) 57
8. Chou K., Wei D., and Zhong W. Biochem. Biophys. Res. Commun. 308 (2003) 148
9. Ghosh A.K., Xi K., Johnson M.E., Baker S.C., and Mesecar A.D. Ann. Rep. Med. Chem. 41 (2006) 183
10. Ghosh A.K., Xi K., Grum-Tokars V., Xu X., Ratia K., Fu W., Houser K., Baker S.C., Johnson M.E., and Mesecar A.D. J. Med. Chem. 48 (2005) 6767
11. Ghosh A.K., Xi K., Ratia K., Santarsiero B.D., Fu W., Harcourt B.H., Rota P.A., Baker S.C., Johnson M.E., and Mesecar A.D. Bioorg. Med. Chem. Lett. 17 (2007) 5876
12. Anand K., Ziebuhr J., Wadhwani P., Mesters J.R., and Hilgenfeld R. Science 300 (2003) 1763
13. Wu C.-Y., King K.-Y., Kuo C.-J., Fang J.-M., Wu Y.-T., Ho M.-Y., Liao C.-L., Shie J.-J., Liang P.-H., and Wong C.-H. Chem. Biol. 13 (2006) 261
14. Thus far, no antiviral activity has been reported for these active ester-derived inhibitors. Inhibitor 3 did not exhibit any antiviral activity in our assay.
15. Blanchard J.E., Elowe N.H., Huitema C., Fortin P.D., Cechetto J.D., Eltis L.D., and Brown E.D. Chem. Biol. 11 (2004) 1445
16. Zhang J., Pettersson H.I., Huitema C., Niu C., Yin J., James M.N., Eltis L.D., and Vederas J.C. J. Med. Chem. 50 (2007) 1850
17. Niu C., Yin J., Zhang J., Vederas J.C., and James M.N. Bioorg. Med. Chem. 16 (2008) 293
18. The indolecarboxylic acids are either from a commercial source or made from hydrolysis of corresponding esters or oxidation of corresponding aldehydes. The starting material for 13 is from Boc protection of 6-aminopenicillanic acid. For preparation of the starting material of 14, 2-acetyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, please see:. Grunewald G.L., Romero F.A., and Criscione K.R. J. Med. Chem. 48 (2005) 134
19. Gribble G.W., and Hoffman J.H. Synthesis (1977) 859
20. Chandra T., Zou S., and Brown K.L. Tetrahedron Lett. 45 (2004) 7783
21. Grum-Tokars V., Ratia K., Begaye A., Baker S.C., and Mesecar A.D. Virus Res. 133 (2008) 63
22. 2. Each condition was set up in triplicate and antiviral assays were performed independently on at least two separate occasions. Cell viability was measured 48 h post infection using the CellTiter-Glo Luminescent Cell Viability Assay (Promega), according to manufacturer's recommendations. Cell viability for the CellTiter-Glo Luminescent Cell Viability Assay was measured as luminescence and output expressed as relative luciferase units (RLU).
23. Authentic SARS-CoV 3CLpro was diluted to 1 μM concentration using cold 20 mM HEPES pH 7.5. Five micrometers of compound 10 was added using a 1:400 dilution into the enzyme solution. The final volume was 200 μL and contained a final DMSO concentration of 0.25%. Control reactions were performed in the same buffer in the presence of 0.25% DMSO in the absence of inhibitor. Incubation was performed at room temperature for 20 min. Sinapinic acid was prepared as a saturating solution in 50% acetonitrile and 1% TFA. The sandwich method of preparation was used for MALDI. One microliters of the matrix was spotted onto a plate followed by 1 μL of the enzyme inhibitor complex followed by a top layering of 1 μL of matrix. A Voyager DE Pro Time of Flight (TOF) mass spectrometer was used for determining the molecular weights.
24. Verschueren K.H.G., Pumpor K., Anemuller S., Chen S., Mesters J.R., and Hilgenfeld R. Chem. Biol. 15 (2008) 597
25. Verdonk M.L., Cole J.C., Hartshorn M.J., Murray C.W., and Taylor R.D. Proteins 52 (2003) 609 and references within
26. Xue X., Yang H., Shen W., Zhao Q., Li J., and Rao Z. J. Mol. Biol. 366 (2007) 965
27. Huitema C., Zhang J., Yin J., James M.N.G., Vederas J.C., and Eltis L.D. Bioorg. Med. Chem. 16 (2008) 5761
28. Niu C., Yin J., Zhang J., Verderas J.C., and James M.N. Bioorg. Med. Chem. 16 (2008) 293